Singapore, April 15, 2008: Japanese biopharmaceutical company AnGes has launched Naglazyme (galsulfase) for patients with the genetic disease mucopolysaccharidosis VI (MPS VI). Naglazyme is the first product commercialized by AnGes.
AnGes has established a marketing and distribution agreement with BioMarin Pharmaceutical, through which AnGes obtained exclusive rights to market Naglazyme in Japan.
Naglazyme was developed to supplement the deficient enzyme in MPS VI by providing an exogenous enzyme in a therapeutic approach known as enzyme replacement therapy (ERT). Naglazyme is already being sold in the US and Europe. In Japan, patient advocacy groups and academic societies have expressed strong interest for the early use of Naglazyme.
| 
Comment on this article
